Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease.

Yilmaz R, Strafella AP, Bernard A, Schulte C, van den Heuvel L, Schneiderhan-Marra N, Knorpp T, Joos TO, Leypoldt F, Geritz J, Hansen C, Heinzel S, Apel A, Gasser T, Lang AE, Berg D, Maetzler W, Marras C.

Front Neurol. 2018 Dec 21;9:1123. doi: 10.3389/fneur.2018.01123. eCollection 2018.

2.

Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay.

Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert ML, Joos TO, Schneiderhan-Marra N.

High Throughput. 2017 Oct 30;6(4). pii: E15. doi: 10.3390/ht6040015.

3.

Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori.

Filomena A, Pessler F, Akmatov MK, Krause G, Duffy D, Gärtner B, Gerhard M, Albert ML, Joos TO, Schneiderhan-Marra N.

High Throughput. 2017 Oct 30;6(4). pii: E14. doi: 10.3390/ht6040014.

4.

Low-picomolar, label-free procalcitonin analytical detection with an electrolyte-gated organic field-effect transistor based electronic immunosensor.

Seshadri P, Manoli K, Schneiderhan-Marra N, Anthes U, Wierzchowiec P, Bonrad K, Di Franco C, Torsi L.

Biosens Bioelectron. 2018 May 1;104:113-119. doi: 10.1016/j.bios.2017.12.041. Epub 2017 Dec 26.

PMID:
29331425
5.

Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.

Filomena A, Guenther A, Planatscher H, Topin F, She J, Formichella L, Terradot L, Gerhard M, Joos TO, Meyer H, Schneiderhan-Marra N.

Proteomes. 2017 Oct 3;5(4). pii: E24. doi: 10.3390/proteomes5040024.

6.

Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.

Bohm K, Filomena A, Schneiderhan-Marra N, Krause G, Sievers C.

Vaccine. 2017 Oct 13;35(43):5883-5889. doi: 10.1016/j.vaccine.2017.08.089. Epub 2017 Sep 14.

7.

Serologic Responses in Childhood Pulmonary Tuberculosis.

Nonyane BAS, Nicol MP, Andreas NJ, Rimmele S, Schneiderhan-Marra N, Workman LJ, Perkins MD, Joos T, Broger T, Ellner JJ, Alland D, Kampmann B, Dorman SE, Zar HJ.

Pediatr Infect Dis J. 2018 Jan;37(1):1-9. doi: 10.1097/INF.0000000000001683.

8.

Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.

Broger T, Basu Roy R, Filomena A, Greef CH, Rimmele S, Havumaki J, Danks D, Schneiderhan-Marra N, Gray CM, Singh M, Rosenkrands I, Andersen P, Husar GM, Joos TO, Gennaro ML, Lochhead MJ, Denkinger CM, Perkins MD.

Clin Infect Dis. 2017 Apr 1;64(7):947-955. doi: 10.1093/cid/cix023.

9.

Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease.

Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W.

Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.

PMID:
28102045
10.

Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2017 Jan;66(1):252-253. doi: 10.1016/j.jhep.2016.10.021. Epub 2016 Nov 15. No abstract available.

PMID:
27863814
11.

A standardized production pipeline for high profile targets from Mycobacterium tuberculosis.

Milewski MC, Broger T, Kirkpatrick J, Filomena A, Komadina D, Schneiderhan-Marra N, Wilmanns M, Parret AH.

Proteomics Clin Appl. 2016 Oct;10(9-10):1049-1057. doi: 10.1002/prca.201600033. Epub 2016 Aug 3.

12.

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7. Erratum in: J Hepatol. 2017 Jan;66(1):252-253.

13.

Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W.

J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.

14.

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.

Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, Ziemssen F, Stahl A.

PLoS One. 2016 Jan 5;11(1):e0145375. doi: 10.1371/journal.pone.0145375. eCollection 2016.

15.

Bead-Based Peptide Arrays for Profiling the Specificity of Modification State-Specific Antibodies.

Filomena A, Beiter Y, Templin MF, Joos TO, Schneiderhan-Marra N, Poetz O.

Methods Mol Biol. 2015;1348:251-65. doi: 10.1007/978-1-4939-2999-3_22.

PMID:
26424278
16.

A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.

Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN; East-German and Swiss Hepatitis C Virus Study Groups.

Hepatology. 2015 Nov;62(5):1375-87. doi: 10.1002/hep.28105. Epub 2015 Sep 28.

PMID:
26250868
17.

Systematic reference sample generation for multiplexed serological assays.

Planatscher H, Rimmele S, Michel G, Pötz O, Joos T, Schneiderhan-Marra N.

Sci Rep. 2013 Nov 19;3:3259. doi: 10.1038/srep03259.

18.

Moving the solid phase: a platform technology for cartridge based sandwich immunoassays.

Gottheil R, Baur N, Becker H, Link G, Maier D, Schneiderhan-Marra N, Stelzle M.

Biomed Microdevices. 2014 Feb;16(1):163-72. doi: 10.1007/s10544-013-9816-2.

PMID:
24091714
19.

Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood.

Schmohl M, Schneiderhan-Marra N, Baur N, Hefner K, Blum M, Stein GM, Joos TO, Schmolz M.

Int Immunopharmacol. 2012 Dec;14(4):722-8. doi: 10.1016/j.intimp.2012.10.010. Epub 2012 Oct 24.

PMID:
23102666
20.

Superficial wound swabbing: a novel method of sampling and processing wound fluid for subsequent immunoassay analysis in diabetic foot ulcerations.

Schmohl M, Beckert S, Joos TO, Königsrainer A, Schneiderhan-Marra N, Löffler MW.

Diabetes Care. 2012 Nov;35(11):2113-20. doi: 10.2337/dc11-2547. Epub 2012 Jul 26.

21.

Establishment of a coculture model for studying inflammation after pediatric cardiopulmonary bypass: from bench to bedside.

Wollersheim S, Fedarava K, Huebler M, Schneiderhan-Marra N, Berger F, Miera O, Schmitt KR.

J Interferon Cytokine Res. 2012 Jun;32(6):269-76. doi: 10.1089/jir.2011.0096. Epub 2012 Apr 27.

22.

Functional analysis of Rho GTPase activation and inhibition in a bead-based miniaturized format.

Schmohl M, Rimmele S, Gierschik P, Joos TO, Schneiderhan-Marra N.

Methods Mol Biol. 2012;827:271-82. doi: 10.1007/978-1-61779-442-1_18.

PMID:
22144281
23.

Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.

Pötz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO.

Methods Mol Biol. 2012;795:191-202. doi: 10.1007/978-1-61779-337-0_13.

PMID:
21960224
24.

A generic operational strategy to qualify translational safety biomarkers.

Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal JM, Molac B.

Drug Discov Today. 2011 Jul;16(13-14):600-8. doi: 10.1016/j.drudis.2011.04.011. Epub 2011 May 6. Review.

PMID:
21570476
25.

Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays.

Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1175-84. doi: 10.1007/s00432-011-0982-4. Epub 2011 Apr 24.

PMID:
21516507
26.

[Protein microarrays and personalized medicine].

Yu X, Schneiderhan-Marra N, Joos TO.

Ann Biol Clin (Paris). 2011 Jan-Feb;69(1):17-29. doi: 10.1684/abc.2010.0512. Review. French.

27.

Bead-based protein-protein interaction assays for the analysis of Rho GTPase signaling.

Rimmele S, Gierschik P, Joos TO, Schneiderhan-Marra N.

J Mol Recognit. 2010 Nov-Dec;23(6):543-50. doi: 10.1002/jmr.1051.

PMID:
21031432
28.

µFBI: a microfluidic bead-based immunoassay for multiplexed detection of proteins from a µL sample volume.

Yu X, Hartmann M, Wang Q, Poetz O, Schneiderhan-Marra N, Stoll D, Kazmaier C, Joos TO.

PLoS One. 2010 Oct 1;5(10). pii: e13125. doi: 10.1371/journal.pone.0013125.

29.

Multiplexed immunoassays for the analysis of breast cancer biopsies.

Schneiderhan-Marra N, Sauer G, Kazmaier C, Hsu HY, Koretz K, Deissler H, Joos TO.

Anal Bioanal Chem. 2010 Aug;397(8):3329-38. doi: 10.1007/s00216-010-3873-7. Epub 2010 Jul 18.

PMID:
20640897
30.

Triple-negative breast cancer: present challenges and new perspectives.

Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium.

Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. Review.

31.

Protein-protein-interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition.

Schmohl M, Rimmele S, Pötz O, Kloog Y, Gierschik P, Joos TO, Schneiderhan-Marra N.

Proteomics. 2010 Apr;10(8):1716-20. doi: 10.1002/pmic.200900597.

PMID:
20127689
32.

Protein microarrays for personalized medicine.

Yu X, Schneiderhan-Marra N, Joos TO.

Clin Chem. 2010 Mar;56(3):376-87. doi: 10.1373/clinchem.2009.137158. Epub 2010 Jan 14. Review.

33.

Protein microarrays: effective tools for the study of inflammatory diseases.

Yu X, Schneiderhan-Marra N, Hsu HY, Bachmann J, Joos TO.

Methods Mol Biol. 2009;577:199-214. doi: 10.1007/978-1-60761-232-2_15. Review.

PMID:
19718518
34.

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X; Tübingen Bevacizumab Study Group, Grisanti S.

Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. doi: 10.1016/j.ophtha.2008.04.023. Epub 2008 Aug 16.

PMID:
18708261
35.

Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion.

Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H.

Clin Cancer Res. 2008 Jun 1;14(11):3345-53. doi: 10.1158/1078-0432.CCR-07-4802.

36.

A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.

Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanović S.

Cancer Res. 2008 Apr 1;68(7):2447-54. doi: 10.1158/0008-5472.CAN-07-2540.

37.

Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1).

Budde A, Schneiderhan-Marra N, Petersen G, Brüne B.

Oncogene. 2005 Mar 3;24(10):1802-8.

PMID:
15674338
38.

Protein Microarrays - A Promising Tool for Cancer Diagnosis.

Schneiderhan-Marra N, Kirn A, Döttinger A, Templin M, Sauer G, Deissler H, Joos TO.

Cancer Genomics Proteomics. 2005 Jan-Feb;2(1):37-42. Epub 2005 Jan 1. Review.

39.

Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo.

Cicha I, Schneiderhan-Marra N, Yilmaz A, Garlichs CD, Goppelt-Struebe M.

Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2046-50. Epub 2004 Sep 23.

PMID:
15388523

Supplemental Content

Loading ...
Support Center